CroíValve, developer of the Duo transcatheter tricuspid coaptation valve system, has announced the appointment of Jaime Wheeler as CEO, replacing Lucy O’Keeffe in the role who will become the company’s chief operating officer.
Wheeler brings more than 25 years of experience having previously served as the senior vice president of global clinical affairs for transcatheter heart valves at Edwards Lifesciences.
CroíValve recently announced the expansion of its TANDEM II study, a US and EU based prospective, multicentre study to evaluate the safety and performance of the Duo Adapt system in patients with severe or greater symptomatic tricuspid regurgitation (TR).
Bernard Collins, chairman of CroiValve, commented: “Jaime brings a proven track record in guiding innovative technologies to market, along with leading high performing teams. Her leadership will be hugely beneficial in guiding the company through its commercialisation journey ahead as we expand our US base and global activities. I would like thank Lucy, on behalf of the board of directors, for her dedication in leading CroíValve successfully through development and initial clinical validation, demonstrating the value proposition of the Duo system.”
Wheeler commented: “What drew me to CroíValve is the calibre of the team and the strength of the science behind the Duo system. I’ve built my career on bringing challenging, innovative technologies to patients and I’m looking forward to doing that here, for our investors and, more importantly, for the patients living with tricuspid regurgitation.”
O’Keeffe added: “As CroíValve looks towards commercialisation, it is the appropriate time to bring in a leader with the right experience for this next phase. Jaime’s exceptional track record of successfully bringing novel transcatheter devices to market is a tremendous asset for CroiValve. I am thrilled to collaborate with her as we embark on this exciting next chapter, accelerating our mission to deliver the Duo System to the patients who need it most.”
